Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2001-09-07
2003-07-22
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S168000, C514S251000, C514S165000, C514S617000, C514S641000, C514S424000, C514S643000
Reexamination Certificate
active
06596708
ABSTRACT:
FIELD OF INVENTION
This invention involves compositions of anti-inflammatory agents for the treatment and prevention of disorders associated with endothelial dysfunction.
BACKGROUND OF THE INVENTION
Endothelial cells are mesodermally derived, simple squamous epithelial cells that line the heart, blood and lymph vessels, line any closed cavity (peritoneal, pleural, pericardial, synovial) and line the intestinal tract. Endothelial cells of blood vessels have both mechanical and functional properties. They provide a barrier effect to the penetration of blood components into the vessel wall and have endocrine functions.
Vascular endothelium is a multi-functional barrier separating blood from interstitium. It plays a role in coagulation, inflammation, angiogenesis and has vasomotor functions. Endothelial dysfunction can be considered as an initial stage of atherosclerosis. Malik J, Melenovsky V, Wichterle D, Function and dysfunction of the endothelium,
Cas Lek Cesk
2000 Apr. 12;139(7):197-202. Endothelium dysfunction is recognized as an early event in the pathogenesis of cardiovascular disease, and linked to hypertension, diabetes mellitus and oxidative stress. Pepine C J, Clinical implications of endothelial dysfunction,
Clin Cardiol
1998 November; 21(11):795-9.
Endothelial dysfunction is characterized by a loss of barrier function and an infiltration of cellular material into the vascular wall and loss of physiological vascular tone. There is a loss of nitric oxide mediated physiological vasodilation, increased endothelial adhesion and migration of leucocytes and macrophages into the subendothelial vascular wall. Hypoxia, shear forces and oxidative stress trigger events for endothelial dysfunction. Disorders associated with endothelial dysfunction include; atherosclerosis, diabetes, infections, inflammations, cardiovascular disease and stroke.
SUMMARY OF THE INVENTION
This invention relates to a composition for the treatment and prevention of endothelial dysfunction consisting of a therapeutically effective amount of anti-inflammatory agents comprising; acetylsalicylic acid, an amino sugar and a zinc compound.
REFERENCES:
patent: 3859436 (1975-01-01), Jacobi
patent: 4006224 (1977-02-01), Prudden
patent: 4049803 (1977-09-01), Cotty et al.
patent: 4867984 (1989-09-01), Patel
patent: 4970081 (1990-11-01), Frisbee
patent: 5364845 (1994-11-01), Henderson
patent: 5437874 (1995-08-01), Bru et al.
patent: 5518738 (1996-05-01), Eickhoff et al.
patent: 5552160 (1996-09-01), Liversidge et al.
patent: 5770215 (1998-06-01), Moshyedi
patent: 5846959 (1998-12-01), Medford et al.
patent: 5948443 (1999-09-01), Riley et al.
patent: 5973011 (1999-10-01), Noack et al.
patent: 6117851 (2000-09-01), Sherman et al.
patent: 6121249 (2000-09-01), Weissman et al.
patent: 6261602 (2001-07-01), Calanchi et al.
McCarty, M.F., Glucosamine May Retard Atherogenesis By Promoting Endothelial Production Of Heparan Sulfate Proteogylcans, Med Hypotheses, Mar. 1997, 48:3, pp. 245-251.*
Caligiuri G, Immune system activated in patients with unstable anginaJ Am Coll Cardiol1998;32:1295-1304.
Di Napoli M, C reactive protein and acute phase of ischemic stroke BMJ 2001;322:1605.
Hingorani AD, et al., New explanation proposed for link between inflammation and cardiac eventsCirculation2000;102:994-999.
Feldman M, Cryer B, Chewing aspirin hastens its anti-platelet effectAm J Cardiol1999;84:404-409.
Frommer DJ, The Healing of Gastric Ulcers by Zinc SulphateMed J of Australia1975;2:793-796.
Gunther T, Rebentisch E, Vormann J, Protection against salycilate ototoxicity by zincJ Trace Elem Electrolytes Health DisMar. 1989;3(1):51-3.
Hart C, Will Super Aspirin Supercede AspirinModern Drug DiscoveryMay/Jun. 1999.
Joseph RM, Varela V, Kanji VK, Subramony C, Mihas AA, Protective effects of zinc in indomethacin-induced gastric mucosal injury: evidence for a dual mechanism involving lipid peroxidation and nitric oxideAliment Pharmacol TherFeb. 1999;12(2):203-8.
Kelly GS, The Role of Glucosamine Sulfate and Chondroitin Sulfates in the Treatment of Degenerative Joint DieseaseAlt Med Rev1998;3(1):27-39.
Kuller LH, Tracy RP, The Role of Inflammation in Cardiovascular DiseaseArteriosclerosis, Thrombosis, and Vascular Biology2000;20(4):901.
Malik J, Melenovsky V, Wichterle D, Function and dysfunction of the endothelium,Cas Lek CeskApr. 12, 2000;139(7):197-202.
Milani RV, Lavie CJ, Pharmacologic prevention of coronary artery diseasePostgraduate Medicine1996;99(2):109-120.
Nissen SE, et al,COX-2 inhibitors linked to increased cardiovascular event rateJAMA2001;286:954-959.
Ochi K, Ohashi T, Kinoshita H, Akagi M, Kikuchi H, Mitsui M, Kaneko T, Kato I, Serum zinc level in patients with tinnitus and the effect of zinc treatmentNippon Jibiinkoka Gakkai KaihoSep. 1997:100(9):915-9.
Pepine CJ, Clinical implications of endothelial dysfunction,Clin CardiolNov. 1998;21(11):795-9.
Pratico D, Aspirin and other nonspecific COX inhibitors may slow atherosclerosisProc Natl Acad Sci USA2001;98:3358-3363.
Rawles J, Importance of Thrombolytic TherapyPre-Hospital Immediate Care1997;1:12-18.
Ridker PM, Inflammation, Infection, and Cardiovascular RiskCirculation1998;97:1671-1674.
Ridker PM, Cushman M, Stampfer MJ,et al, inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy MenNEJM1997;336(14):973-979.
Russell AL, Glycoaminoglycan (GAG) deficiency in protective barrier as an underlying, primary cause of ulcerative colitis, Crohn's disease, interstitial cystitis and possibly Reiter's syndromeMedical Hypothesis1999;52(4):297-301.
Sandercock PAG, Aspirin administration recommended after Ischemic Stroke OnsetLancet1997;349:1563-1565, 1569-1581.
Shambaugh GE Jr., Zinc: the neglected nutrientAm J OtolMar. 1989;10(2):156-60.
Tierney Jr. LM, McPhee SJ, Papadakis MA, Current Medical Diagnosis and Treatment, Appelton & Lange, Norwalk, CN, 3rded 1994 p. 490.
Tindall WN, Cardiac rehab: Movement and medicationBusiness&HealthFeb. 1998.
Quyyumi AA, Endothelial Function in Health and Disease: New Insights into the Genesis of Cardiovascular DiseaseAm J of Medicine1998;105(1A):32S-39S.
Ward SR, Topol EJ, New Strategies for the Prevention of Restenosis after Coronary AngioplastyResident&Staff Physician1995;41(3):11-18.
Zaridze D, Aspirin, other NSAIDs help prevent gastric cancerInt J Cancer1999;82:473-476.
Knarbranda RK et al prevention of Inflammatory-inoculed Endothelial Dysfunction: A Novel Vision-Protteus Action of Aspirin Circulation Jun. 4, 2002; 105(22):2600-4.
Vallenca P, Aspirin Prevents Implament Ion-Induced Endothelial Dysfunction Circulation May 14, 2002;105(22).
Spencer FA et al, Aspirin Use Reduces Severity of Acute Coronary Syndrome in CAD Patients Am J. Cardiol 2002:90:1056-1061.
Porjodes P, Endothelial Dysfunction in Tree Pathogenosis of Athero Scelrorsis Int Angiol Jun. 2002;21(2):109-16.
Alberts U Baby Aspirin, Contor Aspirin May Not Prevent Stroke American Stroke Assn, Phoenix AZ, Feb. 14, 2003.
Advanced Medical Instruments
Fisher La Tonia
Wilson James O.
LandOfFree
Composition for the treatment and prevention of endothelial... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition for the treatment and prevention of endothelial..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition for the treatment and prevention of endothelial... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3052274